IN

$397,398P50FY2010GMNIH

University Of California, San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 38712050 Paper 36354340 Paper 36015010 Paper 35365639 Paper 35364007 Paper 35215956 Paper 35041523 Paper 34821217 Paper 34551310 Paper 34380030 Paper 34166681 Paper 34006103 Paper 33983947 Paper 33970001 Paper 33303586 Paper 33221341 Paper 32989329 Paper 32913054 Paper 32719457 Paper 32238588 Paper 32187548 Paper 32084337 Paper 32060427 Paper 32038048 Paper 31951200 Paper 31866389 Paper 31819258 Paper 31714737 Paper 31582853 Paper 31578291 Paper 31574080 Paper 31570894 Paper 31527793 Paper 31474367 Paper 31447307 Paper 31253590 Paper 31054975 Paper 31044597 Paper 30961890 Paper 30914719 Paper 30853418 Paper 30849700 Paper 30833725 Paper 30821701 Paper 30718774 Paper 30653311 Paper 30559373 Paper 30550790 Paper 30550789 Paper 30514815 Paper 30475902 Paper 30395647 Paper 30308158 Paper 30289719 Paper 30219656 Paper 30209081 Paper 30166484 Paper 30166453 Paper 30118682 Paper 30053425 Paper 30044970 Paper 30033524 Paper 30030465 Paper 30017701 Paper 29995861 Paper 29845934 Paper 29514069 Paper 29364927 Paper 29304101 Paper 29236684 Paper 29168252 Paper 29157200 Paper 28973862 Paper 28961413 Paper 28762184 Paper 28759216 Paper 28494238 Paper 28481362 Paper 28416550 Paper 28388416 Paper 28345603 Paper 28337324 Paper 28331090 Paper 28322550 Paper 28319113 Paper 28299671 Paper 28250466 Paper 28197309 Paper 28158858 Paper 28134250 Paper 28041849 Paper 27992415 Paper 27984726 Paper 27978436 Paper 27977806 Paper 27977742 Paper 27879340 Paper 27783955 Paper 27739665 Paper 27731797

Abstract

PROJECT 1 - IN (STROUD. PROJECT LEADER) Our goal is to understand the mechanism of HIV-1 integration mediated by integrase (IN), in the context of pre-integration complexes (PICs) that provide the targets for anti-IN drugs. The components of PICs, and interactions with viral and cellular proteins will be defined. Our plan builds on our 1.6 A resolution structure of the isolated core domain (IN52"210), our 2.6 A structure of the two-domain catalytic core plus Cterminal domain (IN52"288), and our exclusive ability to prepare homogeneous thiol-linked IN-DNA complexes. We will further analyze the crystal structure of IN without and with its natural substrate, the viral att site and target DNA, and use that knowledge to determine the mechanisms of anti-IN therapeutics.

View original record on NIH RePORTER →